Characteristics of AML patients
| Characteristic . | Value . |
|---|---|
| Sex, no. patients (%) | |
| Male | 40 (56) |
| Female | 31(44) |
| Age, y | |
| Median | 61 |
| Range | 17-85 |
| FAB classification, no. patients (%) | |
| M0 | 2(2.8) |
| M1 | 9(12.6) |
| M2 | 20(28.1) |
| M3 | 4(5.6) |
| M4 | 22(31) |
| M5 | 8(11.3) |
| M6 | 4(5.6) |
| Biphenotypic | 2(2.8) |
| White blood cell count, ×109 cells/L−1 | 10.5 ± 22* |
| NK-cell count, mm3 ± SD | 248 ± 277 |
| Cytogenetic risk group, no. patients (%) | |
| Favorable | 8(11.5) |
| Adverse/intermediate | 63(88.5) |
| Median follow-up, y | 2.65 |
| Complete remission rate, % | 73 |
| Characteristic . | Value . |
|---|---|
| Sex, no. patients (%) | |
| Male | 40 (56) |
| Female | 31(44) |
| Age, y | |
| Median | 61 |
| Range | 17-85 |
| FAB classification, no. patients (%) | |
| M0 | 2(2.8) |
| M1 | 9(12.6) |
| M2 | 20(28.1) |
| M3 | 4(5.6) |
| M4 | 22(31) |
| M5 | 8(11.3) |
| M6 | 4(5.6) |
| Biphenotypic | 2(2.8) |
| White blood cell count, ×109 cells/L−1 | 10.5 ± 22* |
| NK-cell count, mm3 ± SD | 248 ± 277 |
| Cytogenetic risk group, no. patients (%) | |
| Favorable | 8(11.5) |
| Adverse/intermediate | 63(88.5) |
| Median follow-up, y | 2.65 |
| Complete remission rate, % | 73 |
Value is presented as mean ± SD.